General Characteristics
Age: 79 years
Gender: Male
Disease Origin: Clival
Disease Status: Primary
Prior Radiation: No
Prior Systemic Therapy: No
Source: Kevin Mellert, Peter Moller, University of Ulm
Molecular Features
Cell Morphology: Physaliferous
TBXT Expression: Positive; 7x that of U-CH2
TBXT Localization: Nuclear
CD24 Expression: Positive; 3x that of U-CH2
HLA Type:
Sequence Data: WGS and transcriptome data available: raw sequencing data in Cavatica (Chordoma Foundation Dataset) and summary data in PedcBioportal. Contact researchteam@chordoma.org with any questions.
SMARCB1 Status: Wild-type
Validation Results: Validation Report
Growth Conditions
Growth Medium: (4:1) IMDM/RPMI 1640 + 10% FBS + 1% NEAA + 1% GlutaMAX
Freeze Medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing Instructions: Cell Culture Procedures
Publications
Characterized By:
- Sci. Rep. 7:2032-2032(2017). doi=10.1038/s41598-017-02174-5. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas. Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B., von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., Baer A.V., Schultheiss M., Wirtz C.R., Moller P., Mellert K.